On October 19, Shuanglu Pharmaceutical said on an interactive platform, “Hello, the decline in revenue is due to various factors. Sales of many products that have declined significantly in the company's revenue have increased. However, price changes have led to a decline in revenue. The company has abundant product reserves, and many more products will be launched in the future, and the company's competitiveness has not changed much. The company's long-acting GLP-1 has submitted a listing application and is currently under review.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.